OXB — Oxford BioMedica Cashflow Statement
0.000.00%
Last trade - 00:00- £706.82m
- £758.36m
- £128.80m
Annual cashflow statement for Oxford BioMedica, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.69 | 19.9 | -46 | -189 | -47.3 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 4.12 | 5.03 | 1.53 | 106 | 8.55 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -5.15 | -11.9 | 5.47 | 25 | -34.4 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 3.12 | 25.5 | -12.6 | -28.5 | -50.7 |
| Capital Expenditures | -13.4 | -9.46 | -16.3 | -9.83 | -7.5 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 2.56 | 0 | -40.2 | 12.6 | 13.1 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -10.8 | -9.46 | -56.5 | 2.81 | 5.63 |
| Financing Cash Flow Items | -1.72 | -0.873 | -13.9 | -10.2 | -9.43 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 38.2 | 46.2 | 98.6 | -12.7 | 2.91 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 30.5 | 62.2 | 32.3 | -37.6 | -43.1 |